3 results
CAEB071A2206 will assess safety, efficacy and target trough levels for optimal dosing of AEB071 combined with Certican in a CNI-free regimen in de novo renal transplant recipients. This study will combine the investigational drug AEB071 with an…
Procedural success, comprising insertion of the Stentys SDS, deployment of the Stentys Sent in the main branch, withdrawal of the Stentys SDS and creation of the Stentys Sent opening for the sidebranch, without major adverse cardiac events during…
The purpose of this extension is to provide continued treatment and to assess the long term safety, efficacy and tolerability of oral AEB071 plus Certican® vs. Neoral® plus Certican® in de novo renal transplant recipients. The study is a…